Therapeutic potential of coagonists of glucagon and GLP-1

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2014, Pages 126-133

  Patel, Vishal J ^a,b   Joharapurkar, Amit A ^a   Kshirsagar, Samadhan G ^a   Patel, Kartikkumar N ^a   Shah, Gaurang B ^b   Jain, Mukul R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cardiovascular effect; Coagonist; GLP 1; Glucagon and oxyntomodulin

Indexed keywords

AIB2 C24 CHIMERA 2; AIB2 C24 LACTAM 40K; CILOSTAZOL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUALAG; DULAGLUTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; HM 12525A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; METFORMIN; MK 5823; MOD 3060; OXYNTOMODULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; TT 401(LY 2944876); UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ZP 2929; GLUCAGON LIKE PEPTIDE 1;

ARTICLE; BINDING AFFINITY; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HEART PROTECTION; HEMATOLOGIC DISEASE; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THERMOGENESIS; UPREGULATION; WEIGHT GAIN; WEIGHT REDUCTION; AGONISTS; ANIMAL; CARDIOVASCULAR DISEASES; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; OXYNTOMODULIN;

EID: 84924145127     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/1871525712666141019194025     Document Type: Article

References (96)

1. Micha, R.; Michas, G.; Mozaffarian, D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes-an updated review of the evidence. Curr. Atheroscler. Rep., 2012, 14 (6), 515-524.
2. World health organisation, cardiovascular disease facts sheet Available at http://www.who.int/mediacentre/factsheets/fs317/en/ [Accessed on August 2014].
3. International diabetes federation. Available at http://www.idf.org/ diabetesatlas/introduction [Accessed on August 2014].
4. Patel, V.J.; Joharapurkar, A.A.; Shah, G.B.; Jain, M.R. Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia. Curr. Diabetes Rev., 2014, 10 (4), 238-250.
5. Petrovic, D. Candidate genes for proliferative diabetic retinopathy. Biomed. Res. Int. 2013, 27., 540416.
6. Shah, A.; Kanaya, A.M. Diabetes and associated complications in the South Asian population. Curr. Cardiol. Rep., 2014, 16 (5), 476- 476.
7. Starcevic, J.N.; Petrovic, D. Carotid intima media-thickness and genes involved in lipid metabolism in diabetic patients using statins-a pathway toward personalized medicine. Cardiovasc. Hematol. Agents Med. Chem., 2013, 11 (1), 3-8.
8. Goldenberg, R.M. Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents. Can. J. Diabetes, 2011, 35 (5), 518-527.
9. Sheikh, A. Direct cardiovascular effects of glucagon like peptide-1. Diabetol. Metab Syndr., 2013, 5 (1), 47-5.
10. Chan, E.K.; Mackey, M.A.; Snover, D.C.; Schneider, P.D.; Rucker, R.D., Jr.; Allen, C.E.; Buchwald, H. Suppression of weight gain by glucagon in obese Zucker rats. Exp. Mol. Pathol., 1984, 40 (3), 320-327.
11. Day, J.W.; Ottaway, N.; Patterson, J.T.; Gelfanov, V.; Smiley, D.; Gidda, J.; Findeisen, H.; Bruemmer, D.; Drucker, D.J.; Chaudhary, N.; Holland, J.; Hembree, J.; Abplanalp, W.; Grant, E.; Ruehl, J.; Wilson, H.; Kirchner, H.; Lockie, S.H.; Hofmann, S.; Woods, S.C.; Nogueiras, R.; Pfluger, P.T.; Perez-Tilve, D.; DiMarchi, R.; Tschop, M.H. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol., 2009, 5 (10), 749-757.
12. Patel, V.; Joharapurkar, A.; Dhanesha, N.; Kshirsagar, S.; Patel, K.; Bahekar, R.; Shah, G.; Jain, M. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can. J. Physiol Pharmacol., 2013, 91 (12), 1009-1015.
13. Byers, S.O.; Friedman, M.; Elek, S.R. Further studies concerning glucagon-induced hypocholesterolemia. Proc. Soc. Exp. Biol. Med., 1975, 149 (1), 151-157.
14. Pocai, A.; Carrington, P.E.; Adams, J.R.; Wright, M.; Eiermann, G.; Zhu, L.; Du, X.; Petrov, A.; Lassman, M.E.; Jiang, G.; Liu, F.; Miller, C.; Tota, L.M.; Zhou, G.; Zhang, X.; Sountis, M.M.; Santoprete, A.; Capito', E.; Chicchi, G.G.; Thornberry, N.; Bianchi, E.; Pessi, A.; Marsh, D.J.; SinhaRoy, R. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 2009, 58 (10), 2258-2266.
15. Fosgerau, K.S.; Larsen, M.; Baek, S.A.; Meier, E.; Groendahl, C.; Bak, H.H. Combination of long-acting insulin with the dual GluGLP-1 agonist ZP2929 causes improved glycemic control without body weight gain in db/db mice. Diabetes, 2011, 60 (Suppl 1), A418.
16. Zealand Pharma Product pipeline. Available at http://zealandpharma. com/product-pipeline/cardio-metabolic-diseases/zp2929 [Accessed on August 2014].
17. Transition therapeutics inc. Product pipeline. Available at http:// www.transitiontherapeutics.com/technology/pipeline.php [Accessed August 2014].
18. Merck & Co., Inc. Clinical trials Available at http://www.merck.com/ clinical-trials/search.html?kw=5823 [Accessed August 2014].
19. Zealand Pharma Slide presentation by Nancy A. Thornberry. Available at http://www.zealandpharma.com/investors/events/eventarchive/ capital-markets-day-may-6-2014-nyc [Accessed August 2014].
20. Hamni Pharmaceuticals Co., LTD. Product Pipeline Available at http://www.hanmipharm.com/eng/rnd/pipeline_n.asp [Accesse Aug 2014].
21. OPKO Health, Inc Press release Available at http://investor.opko. com/releasedetail.cfm?ReleaseID=841731 [Accessed AUG 2014].
22. Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev., 2007, 87 (4), 1409-1439.
23. Authier, F.; Desbuquois, B. Glucagon receptors. Cell Mol. Life Sci., 2008, 65 (12), 1880-1899.
24. Dunphy, J.L.; Taylor, R.G.; Fuller, P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell Endocrinol., 1998, 141(1-2), 179-186.
25. Pocai, A. Action and therapeutic potential of oxyntomodulin. Mol. Metab., 2013, 3(3), 241-251.
26. Sunj, Y.J.; Jn, S.K.; In, Y.C.; Gyu, H.L.; Young, H.K.; Ja, H.K.; Se, C.K. The novel long acting GLP-1/Glucagon dual agonist HM12525A reduces body weight and improves glycermic control in rodent models. In American Diabetes Association's (ADA) 73th Scientific Sessions; Chicago, IL, 2013; p 1041-P.
27. Szayna, M.; Doyle, M. E.; Betkey, J. A.; Holloway, H. W.; Spencer, R. G.; Greig, N. H.; Egan, J. M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology, 2000, 141 (6), 1936-1941.
28. Meeran, K.; O'Shea, D.; Edwards, C.M.; Turton, M.D.; Heath, M.M.; Gunn, I.; Abusnana, S.; Rossi, M.; Small, C.J.; Goldstone, A.P.; Taylor, G.M.; Sunter, D.; Steere, J.; Choi, S.J.; Ghatei, M.A.; Bloom, S.R. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology, 1999, 140 (1), 244-250.
29. Penick, S.B.; Pinkel, L.E. Jr. Depression of food intake induced in healthy subjects by glucagon. N. Engl. J. Med., 1961, 264:893-7., 893-897.
30. Tan, T.M.; Field, B.C.; McCullough, K.A.; Troke, R.C.; Chambers, E.S.; Salem, V.; Gonzalez, M.J.; Baynes, K.C.; De, S.A.; Viardot, A.; Alsafi, A.; Frost, G.S.; Ghatei, M.A.; Bloom, S.R. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes., 2013, 62 (4), 1131-1138.
31. Martin, J.R.; Novin, D.; Vanderweele, D.A. Loss of glucagon suppression of feeding after vagotomy in rats. Am. J. Physiol., 1978, 234 (3), E314-E318.
32. Felig, P.; Wahren, J.; Sherwin, R.; Hendler, R. Insulin, glucagon, and somatostatin in normal physiology and diabetes mellitus. Diabetes, 1976, 25 (12), 1091-1099.
33. Transition therapeutics inc. Technology update February 2014. Available at www.transitiontherapeutics.com/ir/FactSheet.pdf [accessed August 2014].
34. Prolor BIotech. Long acting reversible pegylated oxyntomodulin- MOD-6030. In 5th diabetes drug discovery and developmental conference; Boston, MA, United States, 2012; p 1041-P.
35. Lao, J.; Hanson, B.; DiMarchi, R.; Pocai, A. Effect of GLP1R/ GCGR dual agonist in monkeys. Diabetes, 2013, 62 (Suppl 1), A257.
36. Bullock, B.P.; Heller, R.S.; Habener, J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide- 1 receptor. Endocrinology, 1996, 137 (7), 2968-2978.
37. Noyan-Ashraf, M.H.; Momen, M.A.; Ban, K.; Sadi, A.M.; Zhou, Y.Q.; Riazi, A.M.; Baggio, L.L.; Henkelman, R.M.; Husain, M.; Drucker, D.J. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 2009, 58 (4), 975-983.
38. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Brand, C.L.; Yellon, D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes, 2005, 54 (1), 146-151.
39. Yin, M.; Sillje, H.H.; Meissner, M.; van Gilst, W.H.; de Boer, R.A. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc. Diabetol., 2011, 10: 85.
40. Dokken, B.B.; Hilwig, W.R.; Teachey, M.K.; Panchal, R.A.; Hubner, K.; Allen, D.; Rogers, D.C.; Kern, K.B. Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation, 2010, 81 (6), 755-760.
41. Kavianipour, M.; Ehlers, M.R.; Malmberg, K.; Ronquist, G.; Ryden, L.; Wikstrom, G.; Gutniak, M. Glucagon-like peptide-1 (7- 36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides, 2003, 24 (4), 569-578.
42. Barragan, J.M.; Rodriguez, R.E.; Blazquez, E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1- (7-36) amide in rats. Am. J. Physiol., 1994, 266 (3 Pt 1), E459- E466.
43. Guerci, B.; Bohme, P.; Kearney-Schwartz, A.; Zannad, F.; Drouin, P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab., 2001, 27 (4 Pt 1), 436-447.
44. Meier, J.J.; Gethmann, A.; Gotze, O.; Gallwitz, B.; Holst, J.J.; Schmidt, W.E.; Nauck, M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia, 2006, 49 (3), 452-458.
45. Chang, G.; Zhang, D.; Liu, J.; Zhang, P.; Ye, L.; Lu, K.; Duan, Q.; Zheng, A.; Qin, S. Exenatide protects against hypoxia/ reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells. Exp. Biol. Med. (Maywood.)., 2014, 239 (4), 414-422.
46. Crajoinas, R.O.; Oricchio, F.T.; Pessoa, T.D.; Pacheco, B.P.; Lessa, L.M.; Malnic, G.; Girardi, A.C. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. J. Physiol Renal Physiol., 2011, 301 (2), F355-F363.
47. Kim, M.; Platt, M. J.; Shibasaki, T.; Quaggin, S.E.; Backx, P.H.; Seino, S.; Simpson, J. A.; Drucker, D.J. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med., 2013, 19 (5), 567-575.
48. Yamamoto, H.; Lee, C.E.; Marcus, J.N.; Williams, T.D.; Overton, J.M.; Lopez, M.E.; Hollenberg, A.N.; Baggio, L.; Saper, C.B.; Drucker, D.J.; Elmquist, J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest., 2002, 110 (1), 43-52.
49. Isbil-Buyukcoskun, N.; Gulec, G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul. Pept., 2004, 118 (1-2), 33-38.
50. Ogawa, S.; Ishiki, M.; Nako, K.; Okamura, M.; Senda, M.; Mori, T.; Ito, S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J. Exp. Med., 2011, 223 (2), 133-135.
51. Viswanathan, P.; Chaudhuri, A.; Bhatia, R.; Al-Atrash, F.; Mohanty, P.; Dandona, P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr. Pract., 2007, 13 (5), 444-450.
52. Nikolaidis, L.A.; Elahi, D.; Hentosz, T.; Doverspike, A.; Huerbin, R.; Zourelias, L.; Stolarski, C.; Shen, Y.T.; Shannon, R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation, 2004, 110 (8), 955-961.
53. Bhashyam, S.; Fields, A.V.; Patterson, B.; Testani, J.M.; Chen, L.; Shen, Y.T.; Shannon, R.P. Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ. Heart Fail., 2010, 3 (4), 512-521.
54. Poornima, I.; Brown, S.B.; Bhashyam, S.; Parikh, P.; Bolukoglu, H.; Shannon, R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ. Heart Fail., 2008, 1 (3), 153-160.
55. Gomez, N.; Touihri, K.; Matheeussen, V.; Mendes Da, C.A.; Mahmoudabady, M.; Mathieu, M.; Baerts, L.; Peace, A.; Lybaert, P.; Scharpe, S.; De M.I.; Bartunek, J.; Vanderheyden, M.; Mc, E.K. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail., 2012, 14 (1), 14-21.
56. Gill, A.; Hoogwerf, B.J.; Burger, J.; Bruce, S.; Macconell, L.; Yan, P.; Braun, D.; Giaconia, J.; Malone, J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc. Diabetol., 2010, 9: 6.
57. Read, P.A.; Khan, F.Z.; Dutka, D.P. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart, 2012, 98 (5), 408-413.
58. Robinson, L.E.; Holt, T.A.; Rees, K.; Randeva, H.S.; O'Hare, J.P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open, 2013, 3 (1), e001986.
59. Ferdinand, K.C.; White, W.B.; Calhoun, D.A.; Lonn, E.M.; Sager, P.T.; Brunelle, R.; Jiang, H.H.; Threlkeld, R.J.; Robertson, K.E.; Geiger, M.J. Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus. Hypertension, 2014, 64 (4), 731-737.
60. Bernink, F.J.; Timmers, L.; Diamant, M.; Scholte, M.; Beek, A.M.; Kamp, O.; Marques, K.M.; Denham, R.N.; Chen, W.J.; Doevendans, P.A.; van Rossum, A.C.; van, R.N.; Horrevoets, A.J.; Appelman, Y. Effect of additional treatment with Exenatide in patients with an Acute Myocardial Infarction: The EXAMI study. Int. J. Cardiol., 2013, 167 (1), 289-290.
61. Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109 (8), 962-965.
62. McCormick, L.M.; Kydd, A.C.; Read, P.A.; Ring, L.S.; Bond, S.J.; Hoole, S.P.; Dutka, D.P. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ. Cardiovasc. Imaging, 2014, 7 (2), 274-281.
63. Thrainsdottir, I.; Malmberg, K.; Olsson, A.; Gutniak, M.; Ryden, L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res., 2004, 1 (1), 40-43.
64. Vuguin, P.M.; Charron, M.J. Novel insight into glucagon receptor action: Lessons from knockout and transgenic mouse models. Diabetes Obes. Metab., 2011, 13 Suppl 1, 144-150.
65. Farah, A.; Tuttle, R. Studies on the pharmacology of glucagon. J. Pharmacol. Exp. Ther., 1960, 129, 49-55.
66. Parmley, W.W.; Glick, G.; Sonnenblick, E.H. Cardiovascular effects of glucagon in man. N. Engl. J. Med., 1968, 279 (1), 12-17.
67. Linhart, J.W.; Barold, S.S.; Cohen, L.S.; Hildner, F.J.; Samet, P. Cardiovascular effects of glucagon in man. Am. J. Cardiol., 1968, 22 (5), 706-710.
68. Farah, A.E. Glucagon and the circulation. Pharmacol. Rev., 1983, 35 (3), 181-217.
69. Kaplan, Y.C.; Hocaoglu, N.; Oransay, K.; Kalkan, S.; Tuncok, Y. Effect of glucagon on amitriptyline-induced cardiovascular toxicity in rats. Hum. Exp. Toxicol., 2008, 27 (4), 321-325.
70. Kruty, F.; Gvozdjak, A.; Bada, V.; Niederland, T.R.; Gvozdjak, J.; Kaplan, M. The effect of glucagon on the heart muscle: Relation between metabolic processes and contractility. Biochem. Pharmacol., 1978, 27 (17), 2153-2155.
71. Murtagh, J.G.; Binnion, P. F.; Lal, S.; Hutchison, K.J.; Fletcher, E. Haemodynamic effects of glucagon. Br. Heart J., 1970, 32 (3), 307-315.
72. Uesaka, T.; Yano, K.; Sugimoto, S.; Ando, M. Glucagon-like peptide isolated from the eel intestine: Effects on atrial beating. J. Exp. Biol., 2001, 204 (Pt 17), 3019-3026.
73. Sowden, G.L.; Drucker, D.J.; Weinshenker, D.; Swoap, S.J. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am. J. Physiol Regul. Integr. Comp Physiol., 2007, 292 (2), R962-R970.
74. Mukharji, A.; Drucker, D.J.; Charron, M.J.; Swoap, S.J. Oxyntomodulin increases intrinsic heart rate through the glucagon receptor. Physiol. Rep., 2013, 1 (5), e00112.
75. Yahata, T.; Habara, Y.; Kuroshima, A. Effects of glucagon and noradrenaline on the blood flow through brown adipose tissue in temperature-acclimated rats. Jpn. J. Physiol., 1983, 33 (3), 367-376.
76. Billington, C.J.; Bartness, T.J.; Briggs, J.; Levine, A.S.; Morley, J.E. Glucagon stimulation of brown adipose tissue growth and thermogenesis. Am. J. Physiol., 1987, 252 (1 Pt 2), R160-R165.
77. Edwards, C. I.; Howland, R.J. Adaptive changes in insulin and glucagon secretion during cold acclimation in the rat. Am. J. Physiol., 1986, 250 (6 Pt 1), E669-E676.
78. Heim, T.; Hull, D. The effect of propranalol on the calorigenic response in brown adipose tissue of new-born rabbits to catecholamines, glucagon, corticotrophin and cold exposure. J. Physiol., 1966, 187 (2), 271-283.
79. Larsen, P.J.; Fledelius, C.; Knudsen, L.B.; Tang-Christensen, M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes, 2001, 50 (11), 2530-2539.
80. Baggio, L.L.; Huang, Q.; Brown, T.J.; Drucker, D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology, 2004, 127 (2), 546-558.
81. Flint, A.; Raben, A.; Rehfeld, J.F.; Holst, J.J.; Astrup, A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int. J. Obes. Relat. Metab. Disord., 2000, 24 (3), 288-298.
82. Matikainen, N.; Manttari, S.; Schweizer, A.; Ulvestad, A.; Mills, D.; Dunning, B.E.; Foley, J.E.; Taskinen, M.R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49 (9), 2049-2057.
83. Caren, R.; Corbo, L. Glucagon and cholesterol metabolism. Metabolism, 1960, 9, 938-945.
84. De, O.M.; Prigge, W. F.; Swenson, D. E.; Grande, F. Role of glucagon on fatty liver production in birds. Am. J. Physiol., 1971, 221 (1), 25-30.
85. Eaton, R.P. Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J. Lipid Res., 1973, 14 (3), 312-318.
86. Guettet, C.; Rostaqui, N.; Navarro, N.; Lecuyer, B.; Mathe, D. Effect of chronic glucagon administration on the metabolism of triacylglycerol-rich lipoproteins in rats fed a high sucrose diet. J. Nutr., 1991, 121 (1), 24-30.
87. Rudling, M.; Angelin, B. Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo. J. Clin. Invest., 1993, 91 (6), 2796-2805.
88. Jaya, P.; Kurup, P.A. Mechanism of hypocholesterolemic action of glucagon. J. Biosci., 1987, 12, 111-114.
89. Longuet, C.; Sinclair, E.M.; Maida, A.; Baggio, L.L.; Maziarz, M.; Charron, M.J.; Drucker, D.J. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab., 2008, 8 (5), 359-371.
90. van, B.L.; Ten Kulve, J.S.; la Fleur, S.E.; Ijzerman, R.G.; Diamant, M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J. Endocrinol., 2014, 221 (1), T1-16.
91. Jensterle, S.M.; Kocjan, T.; Pfeifer, M.; Kravos, N.A.; Janez, A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur. J. Endocrinol., 2014, 170 (3), 451-459.
92. Nauck, M.; Frid, A.; Hermansen, K.; Shah, N.S.; Tankova, T.; Mitha, I.H.; Zdravkovic, M.; During, M.; Matthews, D.R. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 2009, 32 (1), 84-90.
93. Bond, A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc. (Bayl. Univ. Med. Cent.), 2006, 19 (3), 281-284.
94. Ye, Y.; Qian, J.; Castillo, A.C.; Ling, S.; Ye, H.; Perez-Polo, J.R.; Bajaj, M.; Birnbaum, Y. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol., 2013, 304 (1), H131-H141.
95. Birnbaum, Y.; Castillo, A.C.; Qian, J.; Ling, S.; Ye, H.; Perez-Polo, J.R.; Bajaj, M.; Ye, Y. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc. Drugs Ther., 2012, 26 (6), 445-456.
96. Steinberg, H.; Anderson, M.S.; Musliner, T.; Hanson, M.E.; Engel, S.S. Management of dyslipidemia and hyperglycemia with a fixeddose combination of sitagliptin and simvastatin. Vasc. Health Risk Manag., 2013, 9, 273-82.